2025-09-25 - Analysis Report
Okay, here's an analysis of Tempus AI (TEM) based on the information you provided.

## TEM (Unknown Company) Analysis

**Company Overview:** Tempus AI is a company focused on applying AI and data to healthcare, particularly in precision medicine.

### 1. Performance vs. S&P 500 (VOO)

**Numbers:**

*   **TEM Cumulative Return:** 28.13%
*   **VOO Cumulative Return:** 9.73%
*   **Absolute Divergence (Current):** 33.3
*   **Relative Divergence:** 45.8 (based on min/max divergence range of -25.4 to 102.9)

**Analysis:**

TEM has significantly outperformed the S&P 500 (VOO) since its IPO. The absolute divergence is 33.3%, with relative divergence at 45.8, meaning the current outperformance is positioned in the lower half of its historical range.

**Alpha/Beta Analysis (2023-2025):**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2023-2025  | 28.0% | 98.7% | 19.0% | 0.1  | 14.1   |

*   **CAGR:** A CAGR of 28.0% indicates strong growth, but the period is short (2023-2025).
*   **MDD:** A Maximum Drawdown (MDD) of 98.7% is very high, signaling substantial risk.
*   **Alpha:** An Alpha of 19.0% indicates TEM has outperformed its benchmark, even after accounting for market risk.
*   **Beta:** A Beta of 0.1 suggests TEM's price is not very sensitive to market movements (S&P 500).
*   **Cap(B):** Market cap of $14.1 billion

### 2. Recent Stock Price Movement

**Numbers:**

*   **Current Price:** 81.045
*   **Last Market Data:** Price: 81.08, Previous Close: 84.13, Change: -3.63
*   **5-day Moving Average:** 85.735
*   **20-day Moving Average:** 81.318
*   **60-day Moving Average:** 69.1346

**Analysis:**

The stock price closed at 81.045, with the last market showing a price of 81.08, down 3.63 from the previous close of 84.13. The price is currently below the 5-day moving average (85.735) and slightly below the 20-day moving average (81.318), but well above the 60-day moving average (69.1346). This suggests a recent downtrend, but still above its medium-term trend. The recent drop of -3.63 indicates potential volatility or negative sentiment.

### 3. Market Risk Indicators

**Numbers:**

*   **Market Risk Indicator (MRI):** 0.434 (Medium Risk)
*   **RSI:** 57.14
*   **PPO:** -0.7183
*   **Hybrid Signal:** Sell 98.9% of holdings (Cash Ratio: 98% on 2025-09-23)
*   **Recent (20-day) Relative Divergence Change:** 0.7 (+)
*   **Expected Return (%):** NaN

**Analysis:**

*   **MRI:** The MRI of 0.434 suggests a medium level of market risk.
*   **RSI:** An RSI of 57.14 is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** A negative PPO (-0.7183) suggests the short-term moving average is below the long-term moving average, indicating a potential downtrend.
*   **Hybrid Signal:** The "Sell 98.9%" signal is strongly bearish, suggesting a high degree of caution.
*   **Recent Relative Divergence Change:** A positive change of 0.7 in relative divergence indicates a short-term upward trend in its relative performance compared to VOO.
*   **Expected Return:** The "NaN" expected return is concerning, possibly indicating missing or unreliable data.
*   **Last Market Data Issue:** The price change of -3.63 indicates a significant intraday drop, reflecting potential negative sentiment or a specific event impacting the stock.

### 4. Recent News & Significant Events

*   **FDA Clearances:** Multiple news items highlight FDA clearances for Tempus AI's products and platforms, indicating regulatory success and potential growth catalysts (e.g., Tempus xR IVD, cardiac imaging platform).
*   **Analyst Recognition:** Articles mention Tempus AI surging since its IPO and analysts boosting growth outlooks.
*   **Market Growth:** A report on the global cell therapy market size reaching $44 billion points to a favorable industry trend.
*   **Pullback:** One article notes a pullback from a record high, indicating potential volatility.

### 4-2. Analyst Opinions

*   **Consensus:** The analyst consensus is "Buy" (2.15 on a 1-5 scale).
*   **Opinions:** Based on 11 analysts.
*   **Target Price:** The average target price is $73.45, with a high of $98.00 and a low of $60.00. The current price of $81.045 is above the average price target.
*   **Recent Rating Changes:** No recent rating changes were provided.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 예상 EPS |
|--------------|-------|----------|
| 2025-08-08   | -0.22 | -0.22988 |
| 2025-05-06   | -0.24 | -0.26003 |
| 2025-02-24   | -0.18 | -0.15    |
| 2024-11-04   | -0.25 | -0.26608 |
| 2024-08-06   | -0.63 | -0.59    |

**Analysis:**

Tempus AI has consistently reported negative EPS. In most recent quarters, the actual EPS has been slightly better than expected, suggesting some positive progress in managing losses. However, the continued losses are a concern.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.31B  | 61.99%        |
| 2025-03-31   | $0.26B  | 60.69%        |
| 2024-12-31   | $0.20B  | 60.83%        |
| 2024-09-30   | $0.18B  | 58.50%        |
| 2024-06-30   | $0.17B  | 45.50%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-06-30   | $0.31B  | -13.84%  |
| 2025-03-31   | $0.33B  | -20.86%  |
| 2024-12-31   | $0.06B  | -23.10%  |
| 2024-09-30   | $0.05B  | -141.16% |
| 2024-06-30   | $0.10B  | -562.04% |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing, indicating strong growth in the company's operations.
*   **Profit Margin:** The profit margin is very high (above 60% for recent quarters), indicating good efficiency in generating profit from revenue.
*   **Equity:** Equity increased significantly in 2025, reflecting capital raises or retained earnings.
*   **ROE:** Return on Equity (ROE) is negative, reflecting the company's net losses. The sharply negative ROE figures in 2024 are particularly concerning.

### 7. Overall Assessment

**Summary:**

*   **Strong Growth:** TEM has demonstrated significant revenue growth and has outperformed the S&P 500 since its IPO.
*   **High Risk:** The high MDD and negative ROE indicate significant financial risk. The "Sell" hybrid signal is also a red flag.
*   **Positive Catalysts:** Recent FDA clearances and positive analyst sentiment are positive catalysts.
*   **Mixed Signals:** The recent price drop, combined with the negative PPO and "Sell" signal, suggest caution.
*   **Valuation:** The current price is above the average analyst target, suggesting it may be overvalued.

**Recommendation:**

Given the mixed signals, a cautious approach is warranted. While the growth potential is apparent, the high risk, negative profitability, and sell signals suggest that investors should be very careful.

**Key Considerations:**

*   **Profitability:** The company needs to demonstrate a path to profitability. Monitor future earnings reports closely.
*   **Cash Burn:** Keep an eye on the company's cash burn rate. How long can they sustain operations with current cash reserves?
*   **Competition:** Understand the competitive landscape in the AI-driven healthcare space.
*   **Valuation:** Assess whether the current valuation is justified given the company's risk profile and growth prospects.
